Adiso Therapeutics inc: Adiso creates medicines to treat inflammatory diseases, improving the lives of patients and their families. Current inflammatory disease treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, Adiso are advancing an innovative pipeline of small molecules (ADS032, ADS051) and single strain live biotherapeutic products (SS-LBP, ADS024) with novel mechanisms of action.
ADS024 (SS-LBP) has just completed a Phase 1b study for the prevention of recurrent CDI and will be undertaking a Phase 2 study in moderate ulcerative colitis (UC) this year. ADS051 is nearly completing enrollment in a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor (NLRP3 & NLRP1) in discovery phase which is being initially explored in respiratory inflammation, and dermal application with multiple future therapeutic areas to pursue.